**Appendix 1 – Consolidated Health Economic Evaluation Reporting Standards 2022**

**Table A1.** Consolidated Health Economic Evaluation Reporting Standards followed in current study

|  |  |  |  |
| --- | --- | --- | --- |
| **Section** | **Item No** | **Guidance for reporting** | **Reported  [In section]** |
| Title | 1 | Identify the study as an economic evaluation and specify the interventions  being compared. | Yes [Title] |
| Abstract | 2 | Provide a structured summary that highlights context, key methods, results,  and alternative analyses. | Yes [Abstract] |
| Background and objectives | 3 | Give the context for the study, the study question, and its practical relevance  for decision making in policy or practice. | Yes  [Introduction] |
| Health economic analysis plan | 4 | Indicate whether a health economic analysis plan was developed and where  available. | Not available |
| Study population | 5 | Describe characteristics of the study population (such as age range,  demographics, socioeconomic, or clinical characteristics). | Yes  [Methods] |
| Setting and location | 6 | Provide relevant contextual information that may influence findings. | Yes  [Methods] |
| Comparators | 7 | Describe the interventions or strategies being compared and why chosen | Yes  [Methods] |
| Perspective | 8 | State the perspective(s) adopted by the study and why chosen. | Yes  [Methods] |
| Time horizon | 9 | State the time horizon for the study and why appropriate. | Yes  [Methods] |
| Discount rate | 10 | Report the discount rate(s) and reason chosen. | Yes  [Methods] |
| Selection of outcomes | 11 | Describe what outcomes were used as the measure(s) of benefit(s) and harm(s). | Yes  [Methods] |
| Measurement of outcomes | 12 | Describe how outcomes used to capture benefit(s) and harm(s) were measured. | N/A |
| Valuation of outcomes | 13 | Describe the population and methods used to measure and value outcomes. | Yes  [Methods] |
| Measurement and valuation of resources and costs | 14 | Describe how costs were valued. | Yes  [Methods] |
| Currency, price date, and conversion | 15 | Report the dates of the estimated resource quantities and unit costs, plus the currency and year of conversion. | Yes  [Methods] |
| Rationale and description of model | 16 | If modelling is used, describe in detail and why used. Report if the model is  publicly available and where it can be accessed. | N/A |
| Analytics and assumptions | 17 | Describe any methods for analysing or statistically transforming data, any  extrapolation methods, and approaches for validating any model used. | N/A |
| Characterising heterogeneity | 18 | Describe any methods used for estimating how the results of the study vary  for subgroups. | Yes  [Sensitivity analysis, methods] |
| Characterising distributional effects | 19 | Describe how impacts are distributed across different individuals or adjustments made to reflect priority populations | Yes  [Scenario analysis, methods] |
| Characterizing uncertainty | 20 | Describe methods to characterise any sources of uncertainty in the analysis. | Yes  [Scenario analysis, methods] |
| Approach to engagement with patients and others affected by the study | 21 | Describe any approaches to engage patients or service recipients, the general  public, communities, or stakeholders (such as clinicians or payers) in the design of the study. | Yes  [Methods] |
| Study parameters | 22 | Report all analytic inputs (such as values, ranges, references) including uncertainty or distributional assumptions. | Yes [Methods] |
| Summary of main results | 23 | Report the mean values for the main categories of costs and outcomes of interest and summarise them in the most appropriate overall measure. | Yes  [Results] |
| Effect of uncertainty | 24 | Describe how uncertainty about analytic judgments, inputs, or projections affect  findings. Report the effect of choice of discount rate and time horizon, if applicable. | Yes  [Scenario analysis, sensitivity analysis, results] |
| Effect of engagement with patients and others affected by the study | 25 | Report on any difference patient/service recipient, general public, community, or  stakeholder involvement made to the approach or findings of the study. | Yes  [Methods] |
| Study finding, limitations, generalisability, and current knowledge | 26 | Report key findings, limitations, ethical or equity considerations not captured,  and how these could affect patients, policy, or practice. | Yes  [Discussion] |
| Source of funding | 27 | Describe how the study was funded and any role of the funder in the identification, design, conduct, and reporting of the analysis. | Yes |
| Conflicts of interest | 28 | Report authors conflicts of interest according to journal or International Committee of Medical Journal Editors requirements. | Yes |